Accès ouvert
2023
article
OpenAlex
Jonathan R. Roth, Travis Rush, Samantha J. Thompson, Adam R. Aldaher et autres
Alzheimer's disease (AD) is the leading cause of dementia and lacks highly effective treatments. Tau-based therapies hold promise. Tau reduction prevents amyloid-β-induced dysfunction in preclinical models of AD and also prevents amyloid-β-independent dysfunction in diverse disease models, especially those with network hyperexcitability, …
us
(code pays fourni par la source)
2021
article
OpenAlex
Jonathan R. Roth, Travis Rush, Derian A. Pugh, Hunter B. Dean et autres
Abstract Background Alzheimer’s disease (AD) is the leading cause of dementia and lacks disease‐modifying treatments. Tau‐based therapies are attractive and Tau reduction prevents amyloid‐induced dysfunction in preclinical AD models. Tau reduction also prevents amyloid‐independent dysfunction in diverse disease contexts, suggesting that strategies …
us
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Travis Rush, Jonathan R. Roth, Samantha J. Thompson, Adam R. Aldaher et autres
The microtubule-associated protein Tau is strongly implicated in Alzheimer's disease (AD) and aggregates into neurofibrillary tangles in AD. Genetic reduction of Tau is protective in several animal models of AD and cell culture models of amyloid-β (Aβ) toxicity, making it an exciting …
us
(code pays fourni par la source)
Accès ouvert
2019
preprint
OpenAlex
Travis Rush, Jonathan R. Roth, Samantha J. Thompson, Adam R. Aldaher et autres
The microtubule-associated protein Tau is strongly implicated in Alzheimer’s disease (AD) and aggregates into neurofibrillary tangles in AD. Genetic reduction of Tau is protective in several animal models of AD and cell culture models of amyloid-β (Aβ) toxicity, making it an exciting …
us
(code pays fourni par la source)